ALRN Stock Overview
A biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Aileron Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.11 |
| 52 Week High | US$7.42 |
| 52 Week Low | US$1.61 |
| Beta | 2.23 |
| 1 Month Change | -0.47% |
| 3 Month Change | -41.71% |
| 1 Year Change | -46.38% |
| 3 Year Change | -78.46% |
| 5 Year Change | -86.89% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Aug 18
Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?
Dec 30Aileron Therapeutics: An Assessment On A Lottery Ticket
Oct 21Aileron Therapeutics: Solving Chemotherapy's Toxicity
May 01Aileron Therapeutics +31% on insider buying more shares
Jan 08Aileron raises $40M via equity offering
Jan 06Aileron Therapeutics EPS in-line
Nov 13Shareholder Returns
| ALRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.5% | -0.1% | -0.5% |
| 1Y | -46.4% | -6.4% | 23.2% |
Return vs Industry: ALRN underperformed the US Biotechs industry which returned -6.4% over the past year.
Return vs Market: ALRN underperformed the US Market which returned 23.2% over the past year.
Price Volatility
| ALRN volatility | |
|---|---|
| ALRN Average Weekly Movement | 12.2% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALRN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ALRN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 15 | James Windsor | www.aileronrx.com |
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion.
Aileron Therapeutics, Inc. Fundamentals Summary
| ALRN fundamental statistics | |
|---|---|
| Market cap | US$41.82m |
| Earnings (TTM) | -US$29.24m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs ALRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$29.24m |
| Earnings | -US$29.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:04 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aileron Therapeutics, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ying Huang | BofA Global Research |
| Brian Kemp Dolliver | Brookline Capital Markets |
| John Newman | Canaccord Genuity |